Sugi Predict

Sugi Predict / Compounds / SCHEMBL1010304

SCHEMBL1010304

SCHEMBL1010304

COc1ccc(N)cc1OC(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.50
▸ GAA P10253 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ TSHR P16473 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ NR4A1 P22736 1/20 0.49
▸ ALDH1A1 P00352 6/20 0.47
▸ USP2 O75604 1/20 0.47
▸ CYP19A1 P11511 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ PDE4B Q07343 3/20 0.42
▸ ATM Q13315 1/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ CSNK2A1 P68400 1/20 0.40
▸ CYP3A4 P08684 1/20 0.39
▸ IMPDH2 P12268 1/20 0.39
▸ IMPDH1 P20839 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371617 0.92 MAPT (0.55) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL7325807 0.90 ALDH1A1 (0.50) KDM4EGAAMAPTTSHRMAPK1
Hydrochloric Acid SCHEMBL10607534 0.88 ALDH1A1 (0.53) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL77823 0.83 KDM4E (0.67) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL2438047 0.83 KDM4E (0.67) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL29377777 0.83 KDM4E (0.67) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL4323659 0.82 KDM4E (0.49) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL7404286 0.82 KDM4E (0.45) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL13963701 0.82 PDE10A (0.48) KDM4EGAAMAPTTSHRMAPK1
SCHEMBL2088008 0.81 GAA (0.43) KDM4EGAAMAPTTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113563244-B Substituted aza five-membered ring compound and application thereof in medicine 广东东阳光药业股份有限公司 2025-01-10 — — CN disclosed
CN-113563245-B Substituted pyrrolidines and their use in medicine 广东东阳光药业股份有限公司 2024-10-15 — — CN disclosed
WO-2024175086-A1 ARYL TRICYCLIC STING AGONIST AND USE THEREOF 深圳真实生物医药科技有限公司 2024-08-29 — — WO disclosed
CN-116354992-A PDE4 inhibitor and application thereof in medicines 广东东阳光药业有限公司 2023-06-30 — — CN disclosed
CN-113563244-A Substituted aza five-membered ring compound and application thereof in medicine 广东东阳光药业有限公司 2021-10-29 — — CN disclosed
CN-113563245-A Substituted pyrrolidine compounds and application thereof in medicines 广东东阳光药业有限公司 2021-10-29 — — CN disclosed
CN-108368114-A Pyrrolopyrimidine compounds as MNK inhibitor 生命弧度公司 2018-08-03 — — CN disclosed
EP-2346848-B1 QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-02-27 — — EP disclosed
US-8318749-B2 Quinazoline derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-11-27 — — US disclosed
EP-2268632-B1 TERTIARY AMINE DERIVATIVES AS PHOSPHODIESTERASE-4 INHIBITORS CHIESI FARMA SPA (IT) 2012-08-08 — — EP disclosed
US-7452873-B2 Inhibitors of GSK-3 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-18 — — US disclosed
CN-101039946-A Disubstituted pyrazolobenzodiazepines * useful as inhibitors for CDK2 and angiogenesis and for the treatment of breast, colon, lung and prostate cancer HOFFMANN LA ROCHE (CH) 2007-09-19 — — CN disclosed
CN-101012225-A 3-Cyanoquinoline derivative, preparation method and medical use thereof UNIV CHINA PHARMA (CN) 2007-08-08 — — CN disclosed
US-20070149613-A1 Fumagillol derivative and the medical use thereof EQUISPHARM CO., LTD. (KR) 2007-06-28 — — US disclosed
US-20060276512-A1 Fumagillol derivatives and preparing method thereof HAN CHEOL-KYU 2006-12-07 — — US disclosed
US-7087768-B2 6-O-(4-methoxyaniline)acetyl fumagillol for example; superior angiogenesis inhibitory effect with less toxicity, also a cancer metastasis inhibitor, and treats angiogenesis related disorders such as other various inflammatory diseases such as rheumatic disease, psoriasis, and diabetic retinopathy EQUISPHARM CO., LTD. (KR) 2006-08-08 — — US disclosed
EP-1436286-A4 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF IDRTECH INC (KR) 2004-12-15 — — EP disclosed
US-20040242681-A1 Fumagillol derivatives and preparing method thereof EQUISPHARM CO., LTD. (KR) 2004-12-02 — — US disclosed
EP-1436286-A1 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF Idrtech Inc. (KR) 2004-07-14 — — EP disclosed
WO-2003027104-A1 FUMAGILLOL DERIVATIVES AND PREPARING METHOD THEREOF IDRTECH INC. (KR) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242681-A1 Fumagillol derivatives and preparing method thereof FLT1, PGF, FLT4 KDM4E 2573/4885GAA 1126/4885MAPT 212/4885
US-20070149613-A1 Fumagillol derivative and the medical use thereof FLT1, FH, PGF KDM4E 3808/4885GAA 1673/4885MAPT 148/4885
US-20060276512-A1 Fumagillol derivatives and preparing method thereof FLT1, BRAF, FAH KDM4E 3955/4885GAA 1743/4885MAPT 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.